{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:35:58Z","timestamp":1771007758349,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81260231"],"award-info":[{"award-number":["81260231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Basic Research Projects of Jiangxi Province","award":["20143ABC20005"],"award-info":[{"award-number":["20143ABC20005"]}]},{"name":"Jiangxi Provincial Health and Family Planning Commission Science and Technology Program","award":["20155645"],"award-info":[{"award-number":["20155645"]}]},{"name":"Graduate Student Innovation Fund of Jiangxi Province","award":["YC2014-B023"],"award-info":[{"award-number":["YC2014-B023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s12185-016-2028-9","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T09:26:42Z","timestamp":1465205202000},"page":"358-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Xiaoyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaijun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,6]]},"reference":[{"key":"2028_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. New Engl J Med. 1999;340:1330\u201340.","journal-title":"New Engl J Med"},{"key":"2028_CR2","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"M Deininger","year":"1997","unstructured":"Deininger M, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691.","journal-title":"Blood."},{"key":"2028_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"2028_CR4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med. 2006;355:2408\u201317.","journal-title":"New Engl J Med"},{"key":"2028_CR5","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20139.","journal-title":"Blood"},{"key":"2028_CR6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med. 2003;348:994\u20131004.","journal-title":"New Engl J Med"},{"key":"2028_CR7","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","volume":"119","author":"WT Parker","year":"2012","unstructured":"Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Brief report Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012;119:2234\u20138.","journal-title":"Blood"},{"issue":"252","key":"2028_CR8","first-page":"4531","volume":"6","author":"L Ma","year":"2014","unstructured":"Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014;6(252):4531\u20136.","journal-title":"Sci Transl Med."},{"key":"2028_CR9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quintes-Cardama","year":"2009","unstructured":"Quintes-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16:122\u201331.","journal-title":"Cancer Control"},{"key":"2028_CR10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia. 2002;16:2190\u20136.","journal-title":"Leukemia"},{"key":"2028_CR11","first-page":"114","volume":"21","author":"LD Ursan","year":"2015","unstructured":"Ursan LD, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Pharm. 2015;21:114\u201322.","journal-title":"J Manag Care Pharm"},{"key":"2028_CR12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","volume":"25","author":"LF Peterson","year":"2011","unstructured":"Peterson LF, Mitrikeska E, Giannola D, et al. p53 stabilization induces apoptosis in\u2002chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25:761\u20139.","journal-title":"Leukemia"},{"key":"2028_CR13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","volume":"80","author":"RR Nair","year":"2010","unstructured":"Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol. 2010;80:602\u201312.","journal-title":"Biochem Pharmacol"},{"key":"2028_CR14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, Ho YW, Huang Q, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21:577\u201392.","journal-title":"Cancer Cell"},{"key":"2028_CR15","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1007\/s13277-014-2610-9","volume":"35","author":"S Shahrabi","year":"2014","unstructured":"Shahrabi S, Azizidoost S, Shahjahani M, Rahim F, Ahmadzadeh A, Saki N. New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia. Tumor Bio. 2014;35:10627\u201333.","journal-title":"Tumor Bio"},{"key":"2028_CR16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/bjc.2012.201","volume":"106","author":"JM Houthuijzen","year":"2012","unstructured":"Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE. The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer. 2012;106:1901\u20136.","journal-title":"Br J Cancer"},{"key":"2028_CR17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.leukres.2014.02.011","volume":"38","author":"PK Estrada-Gonz\u00e1lez","year":"2014","unstructured":"Estrada-Gonz\u00e1lez PK, G\u00f3mez-Ceja L, Montesinos JJ, Mayani H, Ch\u00e1vez-Gonz\u00e1lez A, Meill\u00f3n L, et al. Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and imatinib-treated chronic myeloid leukemia patients. Leuk Res. 2014;38:594\u2013600.","journal-title":"Leuk Res"},{"key":"2028_CR18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.12725","volume":"164","author":"Y Tabe","year":"2014","unstructured":"Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Brit J Haematol. 2014;164:767\u201378.","journal-title":"Brit J Haematol"},{"key":"2028_CR19","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.cellsig.2012.05.015","volume":"24","author":"PFS Etet","year":"2012","unstructured":"Etet PFS, Vecchio L, Kamdje AHN. Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment. Cell Signal. 2012;24:1883\u20138.","journal-title":"Cell Signal"},{"key":"2028_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00204-014-1226-6","volume":"89","author":"X Li","year":"2015","unstructured":"Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, et al. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway. Arch Toxicol. 2015;89:121\u201336.","journal-title":"Arch Toxicol"},{"key":"2028_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.178.1.257","volume":"178","author":"KH Grabstein","year":"1993","unstructured":"Grabstein KH, Waldschmidt TJ, Finkelman FD, et al. Inhibition of murine B-lymphopoiesis and T lymphopoiesis in vivo by an anti-interleukin-7 monoclonal-antibody. J Exp Med. 1993;178:257\u201364.","journal-title":"J Exp Med"},{"key":"2028_CR22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.smim.2012.04.010","volume":"24","author":"F Carrette","year":"2012","unstructured":"Carrette F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol. 2012;24:209\u201317.","journal-title":"Semin Immunol"},{"key":"2028_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1073\/pnas.86.1.302","volume":"86","author":"RG Goodwin","year":"1989","unstructured":"Goodwin RG, Lupton S, Schmierer A, et al. Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. P Natl Acad Sci USA. 1989;86:302\u20136.","journal-title":"P Natl Acad Sci USA"},{"key":"2028_CR24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.smim.2012.02.005","volume":"24","author":"W Lundstr\u00f6m","year":"2012","unstructured":"Lundstr\u00f6m W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin Immunol. 2012;24:218\u201324.","journal-title":"Semin Immunol"},{"key":"2028_CR25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","volume":"95","author":"F Vianello","year":"2010","unstructured":"Vianello F, Villanova F, Tisato V, Lymperi S, Ho KK, Gomes AR, et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis. Haematologica. 2010;95:1081\u20139.","journal-title":"Haematologica"},{"key":"2028_CR26","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang B, Li M, McDonald T, et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling. Blood. 2013;121:1824\u201338.","journal-title":"Blood"},{"key":"2028_CR27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/leu.2014.156","volume":"29","author":"L Schafranek","year":"2015","unstructured":"Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, et al. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia. 2015;29:76\u201385.","journal-title":"Leukemia"},{"key":"2028_CR28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","volume":"13","author":"K Beider","year":"2014","unstructured":"Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Can Ther. 2014;13:1155\u201369.","journal-title":"Mol Can Ther"},{"key":"2028_CR29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.leukres.2013.11.006","volume":"38","author":"C Quintarelli","year":"2014","unstructured":"Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, et al. Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. Leukemia Res. 2014;38:236\u201342.","journal-title":"Leukemia Res"},{"key":"2028_CR30","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+progenitors via JAK-2\/STAT-5 pathway activation. Blood. 2007;109:2147\u201355.","journal-title":"Blood"},{"key":"2028_CR31","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117:3409\u201320.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2028-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2028-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:30:00Z","timestamp":1600713000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2028-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2028-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,6]]}}}